Objective-In vitro, transglutaminase-2 (TG2)-mediated activation of the β-catenin signaling pathway is central in warfarininduced calcification, warranting inquiry into the importance of this signaling axis as a target for preventive therapy of vascular calcification in vivo. Methods and Results-The adverse effects of warfarin-induced elastocalcinosis in a rat model include calcification of the aortic media, loss of the cellular component in the vessel wall, and isolated systolic hypertension, associated with accumulation and activation of TG2 and activation of β-catenin signaling. These effects of warfarin can be completely reversed by intraperitoneal administration of the TG2-specific inhibitor KCC-009 or dietary supplementation with the bioflavonoid quercetin, known to inhibit β-catenin signaling. Our study also uncovers a previously uncharacterized ability of quercetin to inhibit TG2. Quercetin reversed the warfarin-induced increase in systolic pressure, underlying the functional consequence of this treatment. Molecular analysis shows that quercetin diet stabilizes the phenotype of smooth muscle and prevents its transformation into osteoblastic cells. 
V ascular smooth muscle is characterized by phenotypic plasticity that contributes to cardiovascular disease. Perhaps, the best-studied type is an osteoblast-like vascular smooth muscle transformation in vascular calcification, [1] [2] [3] [4] the condition known as a risk factor for cardiovascular mortality in the general population and in patients with diabetes mellitus and end-stage renal disease. 5, 6 Vascular calcification also associates with atherosclerotic plague burden, cardiac valve calcification, and isolated systolic hypertension, 7 which is prevalent in the elderly population. At present, vascular calcification is not curable, emphasizing the need for a better understanding of its molecular mechanism to advance prevention and therapy.
Cross-sectional studies indicate a link between anticoagulant therapy with Coumadin (warfarin) and calcium phosphate deposition in arterial media, [7] [8] [9] [10] and in the rat model, warfarin treatment induces elastocalcinosis and leads to isolated systolic hypertension. 7, 8 A commonly considered mechanism of warfarin-induced calcification involves inhibition of the vitamin K epoxide reductase enzyme, thereby deactivating carboxylation-dependent vascular proteins, including matrix Gla protein (MGP). 11, 12 Carboxylated MGP prevents vascular calcification directly by inhibiting hydroxyapatite formation 13 and indirectly by inhibiting bone morphogenetic proteins, 14 potent enhancers of osteogenesis. 15 However, despite the efficacy of elevated carboxylated MGP to reverse warfarininduced calcification ex vivo in aortic rings 8 and in vitro, 12 high-dose vitamin K treatment aimed to restore the extrahepatic levels of protein carboxylation in warfarin-treated animals had limited efficacy. 16 Previously, we established in vitro a critical role for canonical β-catenin signaling in warfarin-induced osteoblastlike transformation and calcification of vascular smooth muscle cells (VSMCs). 17 We have also shown that warfarin activates β-catenin in VSMCs via enzyme transglutaminase-2 (TG2), 17, 18 adding to the growing list of non-Wnt agonists of this signaling pathway. 19 Genetic ablation of TG2 protected against aortic calcification in warfarin-treated mice, 17 identifying this enzyme as a potential therapeutic target. Indeed, specific pharmacological inhibition of TG2 prevented warfarin-induced calcification in vitro. 17 However, cultured VSMCs may differ from smooth muscle cells in their vascular niche, 2 and thus the effects of pharmacological TG2 inhibition in vivo may differ from the in vitro observations. In this study, we test the hypothesis that warfarin-induced calcification in vivo associates with activation of the TG2/β-catenin signaling axis and that inhibition of this signaling conduit can prevent elastocalcinosis. We report potent prevention of vascular calcification by the TG2-specific inhibitor KCC-009. 20 In addition, we demonstrate that 3,3ʹ,4ʹ,5,7-pentahydroxyflavone (quercetin), which is a known β-catenin inhibitor in various cells, [21] [22] [23] efficiently prevents warfarininduced medial calcification and its corollaries, and this effect may be mediated by the newly described ability of quercetin to directly inhibit TG2.
Materials and Methods
A detailed description of materials and experimental methods is available in the online-only Data Supplement. Reagents are from Sigma-Aldrich, unless otherwise specified.
Animals
Maintenance and procedures were performed in accordance with the guidelines and regulations of the University of Maryland School Medicine Institutional Animal Care and Use Committee. In vivo studies were performed on 6-to 8-week-old male Wistar rats (Charles River). Animals were treated daily for 4 to 6 weeks with 20 mg/kg vitamin K, 20 mg/kg warfarin, 10 mg/kg quercetin (QU995), 50 mg/kg KCC-009, 20 or 30% dimethyl sulfoxide vehicle. At the end points, animals were anesthetized with isoflurane, and blood pressure was measured using a nylon catheter inserted into the left femoral artery. All animals were euthanized using CO 2 inhalation, followed by thoracotomy.
Statistical Analysis
Data are expressed as mean±SEM. Student t test was used for comparison between 2 groups. For >2 groups, significance was determined using 1-way ANOVA, with comparison between groups by Tukey-Kramer honestly significant difference test. P<0.05 was considered statistically significant; * denotes P<0.05, ** denotes P<0.01, and NS denotes not significant.
Results

The TG2/β-Catenin Signaling Axis Is Activated in Warfarin-Induced Medial Calcification
Medial arterial elastocalcinosis (5.73±0.41 μg calcium/mg dry weight compared with 2.38±0.24 μg Ca/mg dry weight in untreated controls; Figure 1A ) was induced in rats by a 4-week-long treatment with daily dietary supplement of warfarin, coadministered with vitamin K to prevent excessive bleeding, 7, 8 hereafter referred to as WVK treatment. We report a novel morphological observation on the thinning of the aortic wall in WVK-treated animals ( Figure 1B) , which may contribute to the reported decreased arterial compliance in this animal model. 8, 24 However, the lumen diameter of the aortae did not change ( Figure IA in the online-only Data Supplement), suggesting that observed wall thinning is not a simple reflection of widening of the aorta. Morphometric analysis of the ratio between elastic lamellae and collagenous matrix surrounding cells identified with Sirius Red staining revealed a significant 25% reduction in thickness of the nonelastic component in the WVK rats ( Figure 1B , left graph), whereas the elastic lamellae remained unchanged ( Figure 1B Increased expression of osteoblastic genes ( Table) indicates that WVK-induced aortic calcification was accompanied by a switch to an osteoblast-like phenotype in vascular cells. Although the essential regulator of the osteogenic program Runx2 is induced relatively moderately at 53%, a similar change in Runx2 levels has previously been defined as sufficient for the osteogenic transformation of vascular cells ex vivo 25 and in vitro. 26 In cultured VSMC, warfarin stimulates TG2 expression and activity. 17 In agreement, in the calcified aortae of the warfarintreated rats, increased TG2-mediated protein cross-linking has been detected in vivo, 27 and we detect accumulation of the TG2 protein ( Figure IC in the online-only Data Supplement). An original finding in this study is accumulation of nuclear β-catenin protein in the calcified areas and in morphologically normal tissue adjacent to the calcified regions ( Figure 1D , arrows), suggesting that β-catenin activation occurs before calcification rather than in response to extracellular mineral deposition. Activation of the β-catenin pathway was further supported by increased expression of β-catenin/T-cell transcription factor (TCF)-dependent genes axin2, cyclin D1, Tcf4, and Numb (Table) . 28 These results indicate activation of the TG2/β-catenin signaling axis in warfarin-induced vascular calcification.
Next, we analyzed oxidative stress, expression of MGP, and inflammation as potential mechanisms underlying the WVK-induced aortic calcification. Little role for oxidative stress is suggested by minimal changes in the molecular markers of oxidative stress ( Figure ID in the online-only Data Supplement), in contrast to their dramatic 3-to 25-fold induction in other models of arterial dysfunction, 29, 30 and by unchanged levels of reactive oxygen species in WVK-treated animals compared with untreated control animals ( Figure IE in the online-only Data Supplement). Expression of MGP, a vitamin K-dependent inhibitor of matrix calcification, showed a nonsignificant 1.35±0.37-fold increase in the WVK-treated animals, implicating little, if any, role for MGP deregulation. This finding is consistent with the lack of a direct association between MGP expression and warfarin-induced calcification ex vivo. 13 The inflammatory response has been shown to promote atherosclerotic calcification in vivo, 31 although in vitro warfarin induces vascular calcification without a noticeable effect on inflammatory cytokine expression in VSMCs. 17 In the WVK-treated rats, we detected a significant increase in the arterial expression of inflammatory cytokines interleukin 1β, interleukin 6, and tumor necrosis factor α (Table) . Although these results may implicate the local inflammatory response in effecting warfarin-induced changes in the aortic wall, our additional data (discussed below) suggest that it is not causative and that calcification can be prevented in the background of elevated inflammatory cytokines.
Inhibition of TG2 Attenuates Warfarin-Induced Calcification and Activation of β-Catenin
To test whether the catalytic activity of TG2 is essential for WVK-induced arterial calcification, animals were treated daily with 50 mg/kg body weight of the TG2-specific small-molecule inhibitor KCC-009. 20 KCC-009 supplementation almost completely eliminated the WVK-induced mineral deposition in the aorta ( Figure 2A and Figure II in the online-only Data Supplement), with a 96% reduction in the area of aortic sections positively stained for noticeable calcium phosphate deposits (from 18.8% in WVK-treated animals to 0.8% in animals that received both WVK and KCC-009 treatments; Figure 2B ). Similarly, KCC-009 treatment prevented the WVK-induced increase in total calcium extracted from the aortic tissue compared with the untreated control rats (1.73±0.21-fold in WVK-treated rats to 0.76±0.10-fold in WVK-and KCC-009-treated group; Figure 2B ). In addition, KCC-009 counteracted thinning of the tunica media in response to WVK treatment ( Figure 2C ). Whereas rats receiving WVK showed an ≈30% decrease in the thickness of the tunica media, in rats receiving both WVK and KCC-009 the overall thickness was similar to control animals.
Finally, KCC-009 blocked the accumulation of nuclear β-catenin protein in response to WVK treatment ( Figure 2D ), further confirming the critical role of TG2 in mediating warfarin-dependent activation of the β-catenin pathway. 17 These data demonstrate the therapeutic efficacy of TG2 inhibition in warfarin-induced elastocalcinosis. However, KCC-009 treatment also caused an ≈25% widening of the aortae (Figures IA and II in the online-only Data Supplement), via a yet unknown mechanism that may have adverse effects. Combined with the limited data on the in vivo toxicity of KCC-009 in both animal models and human patients, these results justify the need for a better characterized compound to inhibit TG2 in the background of warfarin treatment.
Characterization of Quercetin as a TG2 Inhibitor
We have shown that warfarin-induced calcification in vitro involves direct activation of the TG2 enzyme by warfarin. 17 Based on a known significant overlap between the sets of proteins able to interact with warfarin and the flavonoid quercetin, 32 we hypothesized that quercetin may also interact with TG2 to alter its activity. Direct binding of quercetin to TG2 was demonstrated by a pull-down assay using quercetin-conjugated sepharose beads incubated with purified TG2 protein ( Figure 3A) . Quercetin binding inhibits the catalytic activity of purified TG2 ( Figure 3B ) and negates activation of TG2 by warfarin ( Figure 3C 
Quercetin Inhibits Warfarin-Induced Activation of β-Catenin Signaling in VSMCs
In addition to the newly described ability of quercetin to inhibit TG2, this flavonoid has been characterized as an inhibitor of β-catenin activity in several cell types. [20] [21] [22] Here, we analyzed the impact of quercetin on β-catenin signaling in warfarintreated VSMCs.
The canonical β-catenin signal transduction cascade has been described in several excellent reviews. 19, 28 Accumulation of β-catenin protein, its nuclear localization, and increased activity of the β-catenin/TCF/lymphoid enhancer factor transcriptional complex are all hallmarks of active β-catenin signaling and were analyzed in VSMCs exposed to warfarin alone or warfarin and quercetin (compared with the control mock-treated cells). Quercetin counteracted the warfarin-induced accumulation of β-catenin protein ( Figure 4A) , increase in the percentage of cells with overt nuclear localization of β-catenin ( Figure 4B ), as well as enhanced transcription of the β-catenin-dependent luciferase reporter in a dosedependent manner ( Figure 4C ) and tempered expression of the β-catenin target genes, axin2, cyclin D1, and Tcf4 ( Figure IIIC in the online-only Data Supplement), indicating attenuation of the warfarin effects on β-catenin signaling.
Taking into consideration the essential role of the activated TG2/β-catenin signaling axis in warfarin-induced calcification in vitro 17 and the ability of quercetin to inhibit both TG2 activity and β-catenin signaling (described above), we sought to determine whether quercetin prevents warfarin-induced calcification in VSMC, similar to its inhibitory effect on mineralization in osteoblasts. 33 In wild-type mouse aortic rings, quercetin significantly reduced warfarin-induced calcification, and this effect was lacking in the TG2 -/-aortic tissue ( Figure 4D ), indicating potential therapeutic efficiency of quercetin in WVK-induced elastocalcinosis in vivo and implicating TG2 as a primary target. Ample accumulation of quercetin metabolites in the arterial wall 34 suggests its potential bioactivity in the aortic tissue and further supports its evaluation in the therapy of medial calcification.
Quercetin Prevents Warfarin-Induced Arterial Calcification
Daily supplementation of the WVK treatment with dietary oral quercetin at 10 mg/kg body weight (dose approved by the Food and Drug Administration as safe for human dietary consumption) significantly reduced both the cross-sectional calcified area of the tunica media (from 45% in WVK treatment to 2.6% in WVK+quercetin) and total calcium accrual (from a 2.4±0.17-fold increase compared with untreated control animals down to 1.5±0.08-fold). The calcification values in WVKtreated, quercetin-supplemented animals were not significantly different from the untreated control group ( Figure 5A and 5B and Figure IV in the online-only Data Supplement).
Of clinical importance, quercetin efficiently prevented the WVK-induced isolated systolic hypertension previously reported in this animal model of elastocalcinosis. 7 Although WVK-treated animals were characterized by elevated systolic blood pressure and pulse pressure ( Figure 5C , left graphs), the WVK-treated and quercetin-supplemented group did not significantly differ from the untreated control animals ( Figure 5C , right graphs).
At the molecular level, quercetin attenuated calcification without any significant effect on WVK-induced cytokine expression in aortic tissue (Table) , indicating a minor role for local inflammation in warfarin-induced vascular calcification consistent with other studies. 7 Quercetin attenuated the WVK-induced increase in the expression of osteogenic markers osteocalcin, type I collagen, and Runx2 (Table) and thus prevented osteogenic transformation in vascular cells. Interestingly, osteopontin transcript remained elevated in the WVK-treated rats even in the presence of quercetin, consistent with a proposed role for this protein as a negative regulator of vascular calcification. 35 At the same time, quercetin promoted expression of smooth muscle markers, including smooth muscle 
Quercetin Attenuates Warfarin-Induced Activation of TG2 and β-Catenin in Arterial Tissue
To determine whether quercetin affects the aortic TG2/β-catenin signaling axis in vivo similar to its effects in vitro, TG2 protein and activity and hallmarks of active β-catenin signaling were compared in aortae of rats treated with WVK alone or WVK+quercetin. TG2 protein levels ( Figure 6A ) and catalytic activity ( Figure 6B ) in the aortic tissue of animals treated with WVK and quercetin were not significantly different from the levels in untreated control animals and were significantly lower than those in the WVK-treated group. Similarly, quercetin inhibited the WVK-triggered phosphorylation of glycogen synthase kinase-3β 28 ( Figure 6C ) and accumulation of nuclear β-catenin protein in the aortic media ( Figure 6D β-catenin target genes (Table) . These results are consistent with inhibition of the TG2/β-catenin signaling axis contributing to the quercetin mechanism of action in vascular calcification in vivo.
Discussion
A critical role for TG2/β-catenin signaling axis in warfarininduced osteoblast-like transformation of VSMCs has been demonstrated in vitro, 17 and TG2 activity has been implicated in arterial calcification in warfarin-induced elastocalcinosis in rats. 27 Whereas several transglutaminases are expressed in the aortic tissue, [40] [41] [42] this study demonstrates for the first time the efficacy of the TG2-specific inhibitor KCC-009 in preventing warfarininduced elastocalcinosis. The significance of these findings potentially extends beyond warfarin-induced arterial calcification, given the central role for TG2 in phosphate-induced vascular calcification ex vivo 40 and the augmented transglutaminase activity in atherosclerotic plaque calcification in vivo. 43 In addition, the efficacy of systemic use of KCC-009 demonstrated in this study suggests that other vascular processes that involve transglutaminases and, in particular, TG2, such as endothelial barrier function, small artery remodeling, 44 and vascular stiffness, 45 may be amendable with specific small-molecule inhibitors. However, we have detected an undesirable widening of the aorta in the KCC-009-treated animals, potentially complicating clinical implementation of this particular compound. We describe a promising new strategy for preventing warfarin-induced vascular calcification and its corollaries with quercetin. The advantage of this bioflavonoid over the synthetic inhibitor KCC-009 is that it has a wide safety margin in long-term treatments and has been thoroughly evaluated in clinical studies addressing its therapeutic efficacy in cancer, heart disease, and inflammation. 34, 39 Thus, quercetin is an attractive choice for long-term prevention of vascular calcification in chronic conditions or in the background of long-term warfarin treatment. In addition, quercetin-stimulated expression of VSMC markers probably manifests the phenotypic stabilization of VSMCs and thus potential efficacy of quercetin in other vascular pathologies, such as atherosclerosis, restenosis, and hypertension, which hinge on phenotypic switches in these cells. 46 Indeed, a recent study in mice demonstrates the efficacy of quercetin in attenuation of atherosclerosis, 47 and in humans, quercetin consumption correlates with lower blood pressure and low-density lipoprotein levels and overall reduced cardiovascular disease-related mortality. [48] [49] [50] Although potential drug interactions between quercetin and warfarin have been suggested, 32 there is little direct evidence to date, and concurrent administration of these compounds had no notable adverse side effects in our animal model.
Our aortic ring data are consistent with previous findings that warfarin-induced calcification hinges on TG2 17 and demonstrate that quercetin acts via TG2 as quercetin is not effective in the TG2 -/-aortic rings. Taking into account that inhibition of TG2 by KCC-009 attenuates β-catenin activation and calcium accrual, suggesting the TG2/β-catenin axis is critical for warfarin-induced calcification in vivo similar to the in vitro model, 17 the direct inhibition of TG2 by quercetin and quenching of β-catenin activation by this flavonoid are probably responsible for the high efficacy of quercetin in prevention of elastocalcinosis. Furthermore, quercetin therapy may also be beneficial to prevent calcification of the heart valves and in diabetes mellitus in which β-catenin signaling has been implicated. 1, 14, 51 In addition to the newly described TG2/β-catenin axis, warfarin has been assumed to induce aortic calcification through inhibiting MGP γ-carboxylation, thereby affecting the anticalcific effects of the carboxylated MGP. Indeed, genetic loss of arterial MGP causes extensive aortic calcification. 52 However, warfarin treatment in rat animal model did not reduce arterial expression of MGP according to this study and earlier report, 8 and no correlation has been found between circulating levels of carboxylated MGP and coronary arterial calcium in older adults. 53 Furthermore, carboxylation of MGP may not be critical for attenuation of hydroxyapatite crystal growth by this protein, 8 and the ability of carboxylated MGP to bind and deactivate bone morphogenetic proteins 14 may have little relevance to warfarin-induced aortic calcification because of the limited role of bone morphogenetic protein signaling revealed by ex vivo studies. 13 Thus, it is perhaps not very surprising that high intake of vitamin K aimed to rescue protein γ-carboxylation was only 50% efficient in preventing arterial calcification in rats on the WVK diet, 16 indicating a significant role for other γ-carboxylation-independent mechanism(s), such as TG2/β-catenin activation. It is noteworthy, in this regard, that treatment with the TG2 inhibitor KCC-009 was 100% efficient in blocking warfarin-induced calcification.
In conclusion, we demonstrate that the TG2/β-catenin signaling axis is activated in vivo in warfarin-induced osteogenic transformation in vascular smooth muscle and is a novel therapeutic target in elastocalcinosis. This study advances general understanding of the molecular mechanisms of phenotypic instability in VSMCs and presents a novel preventive strategy for vascular calcification. However, young animals were used in this study to model the warfarin-induced elastocalcinosis that is more common in patients aged >50 years, 9 suggesting that further research is needed to test the efficiency of quercetin in older animals and that caution should be exercised in the extrapolation of the results from the animal studies to clinical applications. In addition, quercetin-based therapy needs further optimization by addressing the potential difference in quercetin accumulation by anatomically distinct vascular beds, the possible impact of the known sex differences in vascular calcification, 54 and the dose-dependent potency of quercetin. Also, the question still remains whether, in addition to inhibition of TG2/β-catenin signaling, quercetin treatment also rescues γ-carboxylation of proteins, including MGP. 
